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A vaccine adjuvant is a vaccine compo-
nent that is used to enhance host immune
responses to the antigens in the vaccine.
While live attenuated vaccines without
adjuvants often stimulate strong immune
responses, they are difficult to be approved
for human use due to potential safety con-
cerns. Subunit vaccines (e.g., protein and
peptide vaccines) can purposely exclude
possible allergens, toxins, and virulent mol-
ecular domains of a pathogen. The restric-
tion of host immune responses to specified
antigenic regions prevents autoimmune
responses and increases vaccine safety.
However, subunit vaccines do not typically
induce strong immune responses. There-
fore, the selection and usage of power-
ful vaccine adjuvants to enhance antigen-
specific immune responses is critical to
successful vaccine development.
Intensive vaccine adjuvant research has
been conducted and reported. As of Jan-
uary 11, 2014, a PubMed search of “vac-
cine and adjuvant” identified 35,000 arti-
cles published since 1948. Large amounts of
high throughput gene expression datasets
related to vaccine adjuvants are also pub-
lically available in centralized reposito-
ries, e.g., the NCBI Gene Expression
Omnibus (GEO). These “big data” cannot
be systematically analyzed without compu-
tational approaches. The specific field of
developing and applying informatics tools
for vaccine adjuvant research and devel-
opment can be called “vaccine adjuvant
informatics”. We have previously described
the “vaccine informatics” that focuses on
the development and application of bioin-
formatics methods for facilitating differ-
ent aspects of preclinical vaccine research
and development, clinical vaccine trials,
and post-licensure vaccine safety and effi-
cacy surveillance (1). As a vaccine compo-
nent, vaccine adjuvants are usually stud-
ied together with vaccines. However, vac-
cine adjuvants are manufactured indepen-
dently, and they can be studied individu-
ally for different purposes. For example,
vaccine adjuvants are often administered
to specific hosts in vivo or cells in vitro
for analysis of their induced immune
responses and adverse effects. Overall, vac-
cine adjuvant informatics addresses scien-
tific questions different from those associ-
ated with the whole vaccines or other vac-
cine components (e.g., vaccine antigens).
Figure 1 illustrates the major aspects of
vaccine adjuvant informatics.
There exist various vaccine adjuvant
informatics tools, including literature
mining, database development, ontol-
ogy data integration and analysis, and
Omics bioinformatics data analysis.
We have recently developed a web-
based vaccine adjuvant database Vaxjo
(http://www.violinet.org/vaxjo) (2). Vaxjo
stores the information of over 100 vaccine
adjuvants and approximately 400 vaccines
that use the adjuvants. To improve data
integration and automated reasoning, the
vaccine adjuvant-related data have been
logically represented in the Vaccine Ontol-
ogy (VO) (3). Biological ontologies are sets
of computer- and human-interpretable
terms and relations that logically rep-
resent biological entities and how they
relate to each other. VO has been found
to be able to improve literature mining of
gene–gene integration (3). Omics-based
informatics is a crucial part of the “systems
vaccinology” for systematic analysis of host
immunity induced by vaccines (4) and vac-
cine components. Omics and informatics
are also critical to the implementation of
the “vaccinomics” strategy for personal-
ized vaccine (including vaccine adjuvant)
adverse event analysis and personalized
vaccine development (5).
Informatics studies support basic and
translational vaccine adjuvant research.
Mechanistic understanding of how innate
immunity is initiated and how it shapes
adaptive B- and T-cell responses has sig-
nificantly influenced the development of
vaccine adjuvants. For example, as parts
of innate immune system, the pattern-
recognition receptors (PRRs), including
Toll-like receptors (TLRs) and nucleotide-
binding oligomerization domain (NOD)
proteins, recognize the pathogen-
associated molecular patterns (PAMPs)
such as bacterial lipopolysaccharide. Many
TLR agonists have been developed as vac-
cine adjuvants to bind to TLRs, promoting
the maturation of antigen presenting cells
(e.g., dendritic cells) and further induction
of adaptive immune responses (6). How-
ever, TLR agonists may also cause severe
adverse effects by stimulating the produc-
tion and release of inflammatory cytokines.
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FIGURE 1 | The scope of vaccine adjuvant informatics research.
The immune responses and efficacy of existing vaccine adjuvants and
adjuvant-containing vaccines can be specifically analyzed using high
throughput Omics-based systems biology studies with the support of strong
informatics data integration and analysis. These studies will elucidate the
molecular mechanisms of protective or adverse immune pathways associated
with vaccine adjuvants, identify gene markers of effective vaccine adjuvant
responses, and support specific vaccine adjuvant and vaccine design. The
large amount of vaccine adjuvant literature can also be utilized for manual and
computer-assisted literature mining, leading to integrated mechanism analysis
and database generation. The data can be logically represented and stored in
biomedical ontologies that further improve literature mining. Vaccine adjuvant
informatics also supports rational design of new adjuvants and selection of
existing adjuvants for new vaccine development.
Omics-based systems biology experiments
and bioinformatics data analyses are able
to provide more insights into the mech-
anisms of the interactions between PRRs
and PAMPs, their downstream pathways,
and how innate and adaptive immune
responses are specifically affected. Such
studies require advanced data process-
ing and statistical data analysis based on
existing knowledge on gene functions and
molecular interaction networks (1).
Many new research areas have not been
well studied but deserve intensive explo-
ration. For example, it is likely that the
immune responses induced by vaccine
adjuvants and antigens can be different but
cooperative. The mechanistic differences
and similarities between vaccine adjuvant-
and antigen-induced host responses and
how these two types of responses inter-
act have not been carefully studied. The
addressing of these questions using a com-
bination of Omics, literature mining, and
informatics methods will likely lead to the
development of new and better vaccine
adjuvants and vaccines. In addition, ratio-
nal vaccine adjuvant design needs to con-
sider the factor of what infectious microbe
or disease a vaccine is targeted for. Our
Vaxjo data analysis has identified many
possible correlations between infectious
microbial agents targeted by vaccines and
the adjuvants used in the vaccines (2).
Out of over 100 adjuvants, it is challeng-
ing to predict which adjuvants are opti-
mal for developing disease-specific vac-
cines. Such a task can be solved by advanced
computational and statistical algorithms.
In the exciting era of post-genomics
and informatics, we also expect the advent
of more advanced computational algo-
rithms, easy-to-use software programs,
and even theoretic breakthroughs that will
provide researchers more capabilities to
conduct vaccine adjuvant research and
development.
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